Losartan versus atenolol-based antihypertensive treatment reduces cardiovascular events especially well in elderly patients: The Losartan Intervention for Endpoint reduction in hypertension (LIFE) study
Adrenergic beta-1 Receptor Antagonists
Angiotensin II Type 1 Receptor Blockers
We showed a greater beneficial effect of losartan versus atenolol-based antihypertensive treatment in the group of patients older than 67 years compared to the group of patients younger than 67 years. This difference was not explained by a more pronounced effect of losartan-based treatment on any of the cardiovascular risk factors demonstrated to have independent prognostic importance.